Results 181 to 190 of about 17,638 (200)

Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update

Oncologist, 2004
Andrea Ardizzoni
exaly  

Topotecan for relapsed small cell lung cancer: A systematic review and economic evaluation

Cancer Treatment Reviews, 2011
Andrew Clegg
exaly  

Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release

European Journal of Pharmaceutics and Biopharmaceutics, 2011
Marize Campos Valadares, Ricardo Neves Marreto, Rodolpho C. Braga   +2 more
exaly  

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

Cancer Chemotherapy and Pharmacology, 2002
Jan H M Schellens, Wim W Ten Bokkel Huinink   +1 more
exaly  

Copper–topotecan complexation mediates drug accumulation into liposomes

Journal of Controlled Release, 2006
Marcel B Bally, Aman Taggar, Euan Ramsay
exaly  

A Dose-Escalating Study of Weekly Bolus Topotecan in Previously Treated Ovarian Cancer Patients

Gynecologic Oncology, 2001
Luis Vaccarello, William A Nahhas, H D Homesley   +2 more
exaly  

Development of a highly stable and targetable nanoliposomal formulation of topotecan

Journal of Controlled Release, 2010
Mark E Hayes, Daryl C Drummond, Byron Hann   +2 more
exaly  

Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer

Annals of Oncology, 2004
C P Belani, J R Jett
exaly  

The Accumulation of Topotecan in 9L Glioma and in Brain Parenchyma with and without Dexamethasone Administration

Journal of Neuro-Oncology, 1999
W J Loos, J H M Schellens, W J Loos
exaly  

Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage

European Journal of Pharmacology, 2001
Jörg Wischhusen, Michael Weller, Ulrike Naumann   +2 more
exaly